Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Hsian-Rong Tseng
University of California Los Angeles, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
CytoLumina Technologies Corp
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Tseng disclosed that he is a co-founder of Cytolumina Technologies and holds (b)(4) of the equity in the company, currently valued at (b)(4). In addition Professor Tseng is the co-inventor of “Nanostructured Substrates for Capturing Circulating Tumor Cells” (UC Case No. 2009-520-02). This has technology has been exclusively licensed to Cytolumina Technologies. This intellectual property, will be further developed in the research. This company was restructured in 2011 as Cytolumina Technologies.
Molecular and Functional Analysis of Single Circulating Melanoma Cells
The goal of this R33 proposal is i) to develop a single-cell isolation technology by coupling a NanoVelcro Chip with Laser MicroDissection (LMD) techniques to enable highly efficient enumeration and specific isolation of viable/preservative-free circulating melanoma cells (CMCs) from blood, and ii) to demonstrate the feasibility of performing molecular and functional analyses of the isolated single CMCs. In collaboration with the UCLA melanoma team, we will validate the clinical utility of the proposed single-CMC molecular assays for dynamically monitoring disease progression, treatment outcomes and drug resistance in melanoma patients treated with BRAF inhibitors.
Filed on June 20, 2013.
Tell us what you know about Hsian-Rong Tseng's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Hsian-Rong Tseng filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Hsian-Rong Tseng | University of California Los Angeles | Conflict of Interest | FetoLumina Technologies Corp. | >$600,000 |
| Hsian-Rong Tseng | Cedars Sinai Medical Center | Conflict of Interest | CytoLumina Technologies Corp., Inc. | $0 - $4,999 |
| Hsian-Rong Tseng | University of California Los Angeles | Conflict of Interest | FetoLumina Technologies Corp. | Value cannot be readily determined |
| Hsian-Rong Tseng | Cedars Sinai Medical Center | Conflict of Interest | CytoLumina Technologies Corp., Inc. | Value cannot be readily determined |
| Hsian-Rong Tseng | University of California Los Angeles | Conflict of Interest | CytoLumina Technologies Corp | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.